What is niraparib, and what is it used for?
Niraparib (marketed as Zejula) is a PARP inhibitor used to treat certain cancers, most often ovarian cancer, including cases linked to DNA repair issues such as BRCA mutations. [1]
What makes niraparib different from other PARP inhibitors?
Like other PARP inhibitors, niraparib targets PARP enzymes involved in DNA repair. PARP inhibitors are used to exploit cancer cells that rely more heavily on DNA repair pathways. The main practical differences between PARP inhibitors usually come down to dosing schedules, side-effect patterns, and which specific cancer settings each drug is approved for. [1]
How is niraparib taken (dose and schedule)?
The dosing approach depends on the indication and patient factors, and it can differ from other PARP inhibitors. Details such as starting dose and any adjustments are typically set by the approved prescribing information for Zejula. [1]
What side effects do patients ask about most?
Common concerns with PARP inhibitors include blood count decreases (such as anemia and low platelets) and related symptoms (fatigue, weakness, bruising/bleeding risk). Patients also ask about nausea and fatigue, which are frequently reported across this drug class. For niraparib, monitoring blood counts is a key part of safe use. [1]
How do clinicians monitor patients on niraparib?
Because niraparib can lower blood counts, clinicians typically monitor complete blood counts during treatment and manage dose interruptions or reductions if counts fall. This monitoring approach is tied to the product’s safety guidance. [1]
Who makes niraparib, and is it still under patent protection?
Niraparib is associated with ongoing intellectual-property activity across formulations and related patents. DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including niraparib (Zejula), which can help determine when specific protections may expire. [2]
For patent/exclusivity context, see: DrugPatentWatch.com (niraparib/Zejula): [2]
---
Sources
- https://www.drugs.com/compare/
- https://www.drugpatentwatch.com/patent/nuvarande-niraparib-ze jula